Article in Nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
IncidentalWorld journal of nuclear medicine · 2026
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 4 institutions in 1 country.
Mayank PatelSection on Medical Neuroendocrinology, Developmental Endocrine Oncology and Genetics Affinity Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Dr., MSC-1109, Bldg. 10, CRC, Room 1E-3140, Bethesda, MD 20892-1109 USA.
Abhishek JhaSection on Medical Neuroendocrinology, Developmental Endocrine Oncology and Genetics Affinity Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Dr., MSC-1109, Bldg. 10, CRC, Room 1E-3140, Bethesda, MD 20892-1109 USA.
Tatjana AnticDepartment of Pathology, University of Chicago Medical Center, Chicago, IL USA.
Sarah M NielsenInvitae, Medical Affairs, San Francisco, CA USA.
Jane E ChurpekDepartment of Medicine, Section of Hematology/Oncology and Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL USA.
Alexander LingDepartment of Radiology, Clinical Center, NIH, Bethesda, MD USA.
Karel PacakSection on Medical Neuroendocrinology, Developmental Endocrine Oncology and Genetics Affinity Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Dr., MSC-1109, Bldg. 10, CRC, Room 1E-3140, Bethesda, MD 20892-1109 USA.ORCID 0000-0002-1489-2471
National Institutes of Health · USUniversity of Chicago · USNational Institutes of Health Clinical Center · USUniversity of Chicago Medical Center · US
Funding
Diagnosis &Pathophysiology of PheochromocytomaZ01HD008735 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PACAK, KAREL · 2001 to 2008
$1.7M
Intramural NIH HHS Z01 HD008735
6 · The paper itself
Abstract
Although rare, a metastatic renal cell carcinoma could present with
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.